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Aim: To estimate type 2 diabetes mellitus (T2DM) prevalence in Russian adults.
Methods: NATION is a national, epidemiological, cross-sectional study, conducted in Russia.
In adults (aged 20–79 years), recruitment was stratified by age, sex, geographic region and
settlement type to obtain a representative sample. Recruitment was in public areas with
high numbers of people. T2DM was diagnosed by glycated haemoglobin A1c (HbA1c) levels
(diabetes: HbA1c 6.5% [48 mmol/mol]; pre-diabetes: HbA1c 5.7 to <6.5% [39 to
<48 mmol/mol]). Socio-demographic and anthropometric data were collected.
Results: Blood samples from 26,620 subjects were available. Overall, 5.4% were diagnosed
with T2DM (previously diagnosed: 2.5%; previously undiagnosed: 2.9%); 19.3% were pre-
diabetic. T2DM prevalence increased with age (up to 70 years) and was higher among
females than males (6.1% vs. 4.7%, p < 0.001). The estimated proportion of subjects with pre-
diabetes and T2DM tended to increase with increasing body mass index. T2DM prevalence
was higher in rural versus urban populations (6.7% vs. 5.0%, p < 0.001).
Conclusion: In the Russian adult population, 19.3% had pre-diabetes, T2DM prevalence was
5.4%, and 54% of subjects with diabetes were previously undiagnosed. These results
may help to develop a new T2DM predictive, preventative and management programme
in Russia.
# 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Prevalence of diabetes mellitus (DM) is growing worldwide and
has reached epidemic proportions in many developing and
most developed countries [1,2]. A recent report noted an* Corresponding author at: Dmitriya Ulianova Street 11, 117036 Mosco
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creativecommons.org/licenses/by-nc-nd/4.0/).estimated prevalence of diabetes of 9.2% (uncertainty interval
4.7–13.3%) for the adult population aged 20–79 years in Russia
[2]. According to this estimated prevalence, in Russia,
12.1 million (uncertainty interval 6.2–17.0 million) people
aged 20–79 years old are thought to have DM in 2015 [2]. Thus,
Russia is ranked fifth in the top 10 countries with the largestw, Russia. Tel.: +7 985 644 7809.
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be reliable as it is extrapolated from diabetes prevalence in the
neighbouring countries. An earlier report gave a rather
conservative estimate of DM prevalence (3.2%, 3.5 million/
110 million adult population of Russia) [3], but sample
populations previously evaluated were not representative of
the general Russian population [4]. Furthermore, more
recently, epidemiological studies in several Russian regions
have shown that DM prevalence may be greater than
previously reported [5]. The inconsistencies in reporting DM
prevalence has led to an assumption that a substantial
number of individuals in Russia remain undiagnosed. Given
the growing economic burden of type 2 DM (T2DM), there is a
need to conduct a well-designed, epidemiological study to
improve the accuracy of prevalence estimates.
In 2013, Russian and French officials met to discuss the
prospect of co-operation for conducting a large-scale, epide-
miological study, the NATION study, to evaluate accurately
T2DM prevalence in Russia [6]. Results of this study would be
useful for Public Health authorities in decision making to
define health priorities, to develop healthier lifestyles and
better diabetes care to eventually reduce T2DM and its
complications.
The aim of the NATION study was to evaluate the
prevalence of T2DM in the adult Russian population, the
relationship of T2DM with age, sex and body mass index (BMI),
and to compare the prevalence between urban and rural
populations. A sampling model was developed to adequately
represent the Russian adult population using population data
from the Russian Population Census [7].
2. Materials and methods
2.1. Study design and recruitment
NATION is a national, epidemiological, cross-sectional study,
which was conducted across the eight districts of the Russian
Federation from September 2013 to February 2015. Sixty-three
regions were included and 188 settlements comprised of 90
cities/towns (urban) and 98 rural settlements. Urban and rural
settlements were defined as per the Federal State Statistics
Service [7]. Details of the recruitment method are shown in
Supplementary Table 1. Adults aged 20–79 years were
recruited by age, sex, geographic distribution and type of
settlement. Recruitment was conducted in public places with
a high concentration of people (e.g. streets, squares, parks and
other community areas) in urban areas, and in the streets of
rural areas. Subjects were consecutively recruited until quotas
for sex, age and settlement type were reached. Any subject
who, when asked, stated that they had T1DM was excluded
from recruitment. Subjects were asked to complete a survey
on socio-economic status, health and lifestyle habits. All
subjects provided written informed consent prior to study
participation. The study was performed in accordance with
applicable ethical principles outlined in the Helsinki Declara-
tion and guidelines for Good Clinical Practice [8,9]. Ethical
approval was provided by the Independent Multidisciplinary
Committee on Ethical Review of Clinical Trials of the
Russian Federation.2.2. Sampling
For the NATION study, a representative sample frame was
constructed based on the general population profile of Russia,
i.e. the distribution of the whole Russian population (aged 20–
79 years) and based on Russian regions (population structure
based on age, sex, and settlement type). These population data
were sourced from the Russian Population Census [7].
A sample size of 26,000 subjects was required so that the
diabetes prevalence could be estimated to within 0.6 percent-
age points of the true value with 95% confidence, assuming an
expected prevalence of diabetes equal to 5%. A multi-stage
selection method with quotas for age, sex and settlement type
was used to design the appropriate sampling frame (see
Supplementary Table 2 for full details).
2.3. T2DM evaluation methodology
A survey based on a structured questionnaire was conducted
(Aston Consulting, Moscow, Russia), BMI (without any outer
clothing and shoes) was assessed, and whole venous blood
samples (2 mL, EDTA tubes; fasting status was not necessary)
were collected during laboratory/mobile unit visits. Blood
samples were kept at 2–8 8C and transported to a central
laboratory (INVITRO, Moscow, Russia) within a maximum of 5
days from collection. HbA1c levels were analyzed by capillary
electrophoresis of whole blood [10] using a Capillarys 2 Flex-
Piercing instrument (Sebia Inc, Norcross, GA, USA). An internal
quality control (QC) was performed daily and the between-run
coefficient of variability (CV) was <4%, and the mean internal
QCs were 5.1% and 5.3%. An external QC of the analysers in the
central laboratory compared with all other laboratories in the
European Reference Laboratory database in 2013, demonstrat-
ed excellent repeatability (CV 1.2%) and linearity (CV 0.9983) of
the method.
Following data collection, several groups were identified:
(1) subjects previously diagnosed as T2DM subjects (anam-
nestic information), pharmacologically treated or not; (2)
subjects previously undiagnosed as T2DM subjects based on
HbA1c 6.5% (48 mmol/mol); (3) subjects defined as having
prediabetes based on HbA1c 5.7% and <6.5% (39 to
<48 mmol/mol) and without a previous T2DM diagnosis.
2.4. Objectives
The primary objective of the NATION study was to evaluate
the prevalence of previously diagnosed and previously
undiagnosed T2DM, and pre-diabetes in the adult Russian
population. Secondary objectives included evaluation of
the urban and rural distributions of T2DM, and T2DM
relationship with demographic characteristics (age and sex)
and BMI.
2.5. Statistical analyses
All data (socio-demographic determinants, anthropometric
measurements, HbA1c results, and survey responses) were
entered into a unified database after the field phase. Statistical
analyses were performed using standard data processing
packages (SPSS statistical software, version 20.0; SPSS Inc.,
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(frequency distribution, absolute values, estimated percent-
age distribution, mean values, etc.) were used to identify
general characteristics pertaining to the study outcomes and
to compare data distribution across various groups. Non-
parametric comparison tests on two or more independent and
dependent samples (Mann Whitney U-test, Kolmogorov–
Smirnov test, Waldo–Wolfowitz test, Wilcoxon test, chi-
squared test, binominal test) were applied to assess differ-
ences between parametric and non-parametric data groups.
Parametric methods (standard error of the mean, standard
deviation, 95% confidence intervals [CI], variance, minimum/
maximum and Student’s t-test) were used to assess differ-
ences between two groups of approximately normally
distributed, quantitative data. For T2DM risk evaluation,
relative risk and odds ratio were evaluated for pair groups
(males vs. females, body mass index <25 vs. 25 kg/m2, urban
vs. rural settlement). For age analyses, the data were split into
categories of 5-year ranges. These 5-year ranges were then
combined, as required, for further analysis. As the NATION
study population was representative and in proportion with
the whole population of Russia, i.e. distribution of age and
gender, results were not normalized to account for differences
in number and age.
3. Results
3.1. Study population
Out of 27,252-screened subjects, 26,620 were eligible and
included in NATION. Blood samples collected from 632 subjects
were lost or haemolysed during transportation and were not
analyzed. Fifty-five percent of subjects (n = 14,611) were female.
The overall mean (standard deviation [SD]) age of females, 46.5
(16.3) years, was significantly higher than for males, 43.2
(15.4) years ( p < 0.001). The distribution of the NATION
population by sex and age is shown in Supplementary Fig. 1a.
3.2. Prevalence of T2DM and pre-diabetes
In the NATION study, overall, 5.4% (1449/26,620; 95% CI: 5.1–
5.7%) of subjects were diagnosed with T2DM. Among them,
668 (2.5% of overall study population; 95% CI: 2.3–2.7%) had16.0
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Fig. 1 – Prevalence of previously diagnosed anpreviously diagnosed T2DM, and 781 (2.9% of overall study
population; 95% CI: 2.7–3.1%) had previously undiagnosed
T2DM. Thus, the proportion of previously undiagnosed T2DM
subjects was 54%. Of the 668 subjects reporting a previous
T2DM diagnosis, 3.4% (23/668) were not receiving antihyper-
glycaemic therapy and 2.4% (16/668) had HbA1c 6.5%
(48 mmol/mol). Of the T2DM subjects, 19.3% (278/1449; 95%
CI: 18.8–19.8%) had an HbA1c >9% (>75 mmol/mol). Among
subjects with previously undiagnosed T2DM, the mean HbA1c
was 7.9% (63 mmol/mol) vs. 7.4% (57 mmol/mol) among
subjects with previously diagnosed T2DM ( p < 0.001). Of the
NATION study population, 19.3% (5128/26,620; 95% CI: 18.8–
19.7%) had pre-diabetes.
3.3. Prevalence of T2DM by age and sex
T2DM prevalence increased with age (up to 69 years) then
decreased slightly from 70 years. The ratio of previously
diagnosed and undiagnosed T2DM also increased with age
(Fig. 1). The overall prevalence of T2DM (regardless of age) was
significantly higher in females versus males (884/14,611 [6.1%;
95% CI: 5.7–6.5%] vs. 565/12,009 [4.7%; 95% CI: 4.3–5.1%],
respectively, p < 0.001). In subjects with T2DM, mean age was
significantly higher in females versus males (60.1 vs. 54.8 years,
p < 0.001). There were no significant differences between males
and females in T2DM prevalence in the age categories 20–44
years (1.4% vs. 1.3% for males and females, respectively) and
45–59 years (7.9% vs. 7.0% for males and females, respectively).
In subjects aged 60–79 years, T2DM prevalence was significantly
higher in females versus males (14.1% vs. 9.9%, p < 0.001).
Overall, of the subjects with T2DM, a higher proportion of
females had previously diagnosed T2DM (442/884, 50%) than
males (226/565, 40%) ( p = 0.004). The proportions of previously
diagnosed T2DM for females versus males varied within
different age categories: 40% and 23% in subjects <44 years
(not significant), 49% vs. 42% in subjects 45–59 years (not
significant) and 52% vs. 45% in subjects >60 years ( p < 0.001),
respectively (Fig. 2).
3.4. Prevalence of T2DM by BMI
In NATION, the proportion of subjects who were normal
weight (BMI <25 kg/m2), overweight (BMI 25 to <30 kg/m2) or
obese (BMI 30 kg/m2) was 34%, 35% and 31%, respectively.9
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Fig. 2 – Prevalence of previously diagnosed and undiagnosed T2DM, by sex and age.
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 1 5 ( 2 0 1 6 ) 9 0 – 9 5 93Prevalence of obesity in subjects 45 years was significantly
higher in females versus males ( p < 0.001). The proportion of
subjects with pre-diabetes and T2DM increased with increas-
ing BMI. In the BMI <25 kg/m2 group, the prevalence of T2DM
was 1.1%, and the prevalence of pre-diabetes was 7.4%. In the
BMI 25 to <30 kg/m2 group, the prevalence of T2DM was 3.9%,
while the prevalence of pre-diabetes was 18.6%. Among the
population classified as obese (BMI 30 kg/m2), the prevalence
of T2DM was 12.0% and that of pre-diabetes was 33.1%. These
findings indicate a significant increase of the prevalence of
T2DM between normal weight and obese subjects ( p < 0.001).
In the overall study population, in overweight and obese
groups, HbA1c was higher than in the normal weight group
(mean HbA1c 5.5% [37 mmol/mol], overweight; 5.8% [40 mmol/
mol] obese; 5.3% [34 mmol/mol] normal weight).
The prevalence of T2DM in obese subjects was similar in
females and males in all age groups (20–44, 45–59, and 60–79
years of age).
3.5. T2DM prevalence by settlement type
The proportion of subjects with T2DM was significantly higher
in the rural population compared with the urban population
(427/6333 [6.7%; 95% CI: 6.1–7.3%] vs. 1022/20,287 [5.0%; 95% CI:
4.7–5.3%], respectively, p < 0.001). The proportion of subjects
with previously diagnosed T2DM was 3.0% (188/6333; 95% CI:
2.6–3.4% in the rural population) and 2.4% (480/20,287; 95% CI:
2.2–2.6% in the urban population) ( p < 0.001). The proportion
of subjects with previously undiagnosed T2DM was 3.8% (239/
6333; 95% CI: 3.3–4.3% in the rural population) and 2.7% (542/
20,287; 95% CI: 2.5–2.9% in the urban population) ( p < 0.001).
Average BMI and age were both higher in rural settlements
compared with urban settlements (28.1 vs. 27.0 kg/m2,
p < 0.001; and 48 years vs. 43 years, p < 0.001, respectively).
4. Discussion
NATION is the first, national, epidemiological, cross-sectional
study with the primary aim to evaluate the prevalence ofT2DM in the Russian adult population. Using population data
(age, sex, geographic distribution and settlement type) from
the Russian Population Census [7], a representative sample
was constructed for the NATION study. The NATION study
results demonstrate a 5.4% T2DM prevalence in the Russian
adult population with an uneven distribution when stratified
by settlement type.
A key element of the NATION study was to recruit a sample
population representative of the Russian adult population.
More females than males were recruited, and the overall mean
age of females was higher than for males. Furthermore, the
proportion of younger subjects in the NATION study (20–44
and 45–59 years) was greater than that of older participants
(60–79 years), with more females than males within each age
category. This distribution of the NATION study population by
sex and age is similar to that of the overall Russian population
reported in the last census [7] (Supplementary Fig. 1b). Thus,
given the validity of the population sample, data from the
NATION study can be extrapolated to the general Russian
population.
A previous estimate of T2DM prevalence (previously
diagnosed) in Russia was 3.2% [3], which is similar to the
prevalence of previously diagnosed T2DM in the NATION
study. The agreement between the NATION study and the
State Diabetes registry estimates of the prevalence of
previously diagnosed T2DM confirm the validity of the latter.
The small difference between these prevalence estimates
could be explained by the recruitment of subjects in public
places in the NATION study (a study limitation). Extrapolation
of the T2DM prevalence reported in the NATION study
indicates that, in the adult Russian population aged 20–79
years, 5.9 million people, estimated using Federal State Stats
Service, 2010 data (108 million people aged 20–79 years) were
likely to have T2DM. The NATION study also shows that a
substantial proportion (54%) of T2DM cases are not diag-
nosed in Russia. Previously diagnosed T2DM was found more
frequently than previously undiagnosed T2DM in subjects
aged 65 years old, which may be due to an increase in
screening for diabetes in older people. In addition, the NATION
study reported a high prevalence of pre-diabetes (19.3%),
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people in Russia in 2014. The NATION study also reported a
high incidence of subjects with T2DM with Hb1Ac >9%, who,
therefore, require urgent appropriate antihyperglycaemic
treatment.
In the NATION study, T2DM prevalence increased with age,
which is in keeping with previous reports [2,11]. The highest
T2DM prevalence in the NATION study was in subjects aged
65–69 years, which is consistent with recent US data, where
the prevalence of T2DM in subjects 65 years is 24.7% [11]. This
finding is important, as in this age group there is a high
prevalence of cardiovascular disease, management of which is
more difficult in the presence of diabetes [12,13]. Although
T2DM prevalence increased with age, in those aged 70 years
it does not increase. This observation may be linked to survival
bias with a high mortality rate due to increased risk of
cardiovascular disease in subjects with diabetes at a younger
age [14].
With regard to sex, the present study indicated that T2DM
prevalence was significantly greater among females versus
males in the whole study population. This finding is in
contrast with earlier reports where the prevalence of T2DM
is generally higher in males than females [2,15,16]. In the
NATION study, the sex difference in T2DM prevalence may
be driven by age, as the female population is significantly
older than the male one, which is supported by age-
adjustment of T2DM prevalence demonstrating no signifi-
cant differences between males (5.1%; 95% CI: 4.8–5.4%) and
females (5.6%; 95% CI: 5.3–5.9%). Additionally, considering
results across the different age groups, the higher T2DM
prevalence in females versus males was only statistically
significant in subjects aged 60 years, which may be
explained by a survival bias due to higher cardiovascular-
related mortality in men than in women [17–19]. Interest-
ingly, the proportion of females with previously diagnosed
T2DM was higher than in males across nearly all age groups.
This observation may reflect a more frequent screening of
women for T2DM, e.g. during pregnancy and menopause or
due to more frequent obesity. The NATION study also
demonstrated that T2DM prevalence increased with increas-
ing BMI and obesity, as would be expected as obesity is a
causal risk factor for T2DM [20].
When stratified by settlement type, T2DM prevalence was
found to vary in urban or rural areas. Interestingly, the
proportion of subjects with T2DM was significantly higher in
those living in rural versus urban settlements. This difference
in T2DM rates may be explained by the finding that BMI and
age were both significantly higher in rural areas versus urban
areas.
Strengths of the NATION study include the recruitment of
subjects based on the population distribution of the whole
Russian population, as reported by the Russia Population
Census [7]. The ratio of females to males in the NATION study
was 55:45%. This ratio is consistent with that reported for the
overall Russian population i.e. 54:46% [7], that has been stable
from 1926 to 2014. Also, there was a predominance of younger
subjects in the NATION study population. This is particularly
relevant given that Russia has a younger population distribu-
tion when compared with other European countries [21].
Indeed, normalizing the NATION study data based on theEuropean age structure in accordance with Eurostat statistics
indicates a standardized prevalence of T2DM of 5.9%. One
limitation of the NATION study is that initial patient diagnosis
categorization was based on self declaration, with subsequent
HbA1c testing. Additionally, the use of HbA1c alone as a tool
for the diagnosis of T2DM may not be sufficient. The adoption
of HbA1c is a relatively new approach for the diagnosis of
diabetes, which has yet to be fully standardized. Well known
factors, such as anaemia [22] or certain chronic diseases [23]
can affect HbA1c values. Other investigations have concluded
that using HbA1c alone could result in under-diagnosis of
T2DM [24,25], or that this test should be combined with other
tests to improve detection rates (e.g. fasting glucose [26]). On
the other hand, other studies have demonstrated that HbA1c
is a useful tool for diabetes screening (e.g. [27]). Another
limitation of the NATION study is that the results represent
T2DM prevalence only in the most active population (e.g. those
individuals who frequent public areas). T2DM prevalence in a
less-active population (e.g. those who are more likely to be
house-bound due to age and/or underlying co-morbidities) is
likely to be even higher. This should be considered amongst
the possible factors influencing the decline of prevalence in
older ages.
In conclusion, the NATION study is the first, national,
epidemiological, cross-sectional study conducted in Russia to
evaluate the nationwide prevalence of T2DM. As hypothe-
sized, the prevalence of T2DM in the adult Russia population
was higher than previously registered [3], with more than 50%
of subjects having undiagnosed T2DM. These findings high-
light a growing concern for the national burden of T2DM
across Russia. The increasing prevalence of T2DM with the
risk of diabetes-related complications will undoubtedly add to
health care requirements. The results of the NATION study
provide valuable information to support the design and
implementation of an effective prevention and management
national diabetes programme in Russia.
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